Xcout Intel
Starton Holdings, Inc.
Starton Therapeutics is a clinical-stage biotechnology company that develops proprietary continuous delivery technology systems to improve standard-of-care cancer therapies. The company utilizes subcutaneous, oral, and transdermal delivery platforms to transform FDA-approved active ingredients for superior patient outcomes.
Subscribe to see Starton Holdings, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Starton Holdings, Inc. at a glance
Starton Holdings, Inc. is a biotechnology company headquartered in United States. Xcout tracks 11 named people at Starton Holdings, Inc., including Pedro Lichtinger (Chairman CEO).
Starton Holdings, Inc. leadership
- Pedro LichtingerChairman CEO
- Scott KahnChief Financial Officer
- Jamie OliverChief Medical Officer
- Rod HartwigVP Research and Development/Manufacturing
- Roy F WaldronSenior VP Associate General Counsil and Chief Intellectual Property Council, Pfizer Inc (Retired)
- ERIC BAUMManaging Director, Acquis Consulting and Solidea Capital
5 more named people on record for Starton Holdings, Inc., with roles, board committees and tenure — see the full roster →
Recent Starton Holdings, Inc. news
Starton Holdings, Inc. competitors
A few of Starton Holdings, Inc.'s closest competitors — see the full list of competitors and alternatives →
Star Therapeutics is a biotechnology company that discovers and develops antibody therapies to treat patients with serious diseases. The company focuses on creating patient-centric medical solutions to address real-world healthcare needs.
St. James Therapeutics is a clinical-stage biopharmaceutical company that develops specialized topical skincare products to treat chemotherapy-induced side effects, specifically hand-foot syndrome. The company serves cancer patients by creating science-backed solutions designed to make cancer treatment more tolerable.
Surface Oncology is a clinical-stage biotechnology company focused on developing immunotherapies that target the tumor microenvironment and enhance anti-tumor immune responses. Its programs are intended for cancer patients and are developed for use by oncology physicians and healthcare systems, with potential pharmaceutical partnerships.
Curon Biopharmaceutical is a clinical-stage biotechnology company developing antibody-based medicines, including bispecific antibodies, for cancer and other serious diseases. It serves patients and healthcare providers through the development of therapeutic biologics, with programs intended for oncology and immunology applications.
Cybrexa Therapeutics is a clinical-stage oncology biotechnology company that develops tumor-targeting peptide-drug conjugates (PDCs) for cancer patients. Its proprietary alphalex technology uses a pH-driven approach for antigen-independent, intracellular delivery of anti-cancer agents directly to tumors and metastases.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Get Starton Holdings, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Starton Holdings, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 4 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access